BVS Insider Trading
Insider Ownership Percentage: 32.90%
Insider Buying (Last 12 Months): $902,025.00
Insider Selling (Last 12 Months): $840,174.22
Bioventus Share Price & Price History
Current Price: $9.03
Price Change: ▼ Price Decrease of -0.06 (-0.66%)
As of 03/28/2025 05:00 PM ET
Bioventus Insider Trading History
Bioventus Institutional Trading History
Data available starting January 2016
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Read More on Bioventus
Volume
251,471 shs
Average Volume
431,244 shs
Market Capitalization
$739.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86
Who are the company insiders with the largest holdings of Bioventus?
Bioventus' top insider shareholders include:
- John A Bartholdson (Director)
- Juniper Investment Company, Ll (Major Shareholder)
- William A Hawkins (Director)
- Anthony P Bihl III (CEO)
- Mark Leonard Singleton (CFO)
- Anthony D'adamio (SVP)
- John Nosenzo (Insider)
- Robert E Claypoole (CEO)
- Katrina J Church (SVP)
Learn More about top insider investors at Bioventus.
Who are the major institutional investors of Bioventus?
Bioventus' top institutional shareholders include:
- Nantahala Capital Management LLC — 4.96%
- Vanguard Group Inc. — 3.03%
- Driehaus Capital Management LLC — 1.38%
- American Century Companies Inc. — 1.09%
- Nuveen Asset Management LLC — 0.96%
- Royce & Associates LP — 0.90%
Learn More about top institutional investors of Bioventus stock.
Which institutional investors are selling Bioventus stock?
During the previous quarter, BVS stock was sold by these institutional investors:
- Nantahala Capital Management LLC
- Invesco Ltd.
- Marshall Wace LLP
- D. E. Shaw & Co. Inc.
- Simplex Trading LLC
- Cubist Systematic Strategies LLC
- Connor Clark & Lunn Investment Management Ltd.
- Millennium Management LLC
Within the previous year, company insiders that have sold Bioventus company stock include:
- John A Bartholdson (Director)
- Juniper Investment Company, Ll (Major Shareholder)
- William A Hawkins (Director)
- Anthony P Bihl III (CEO)
Learn More investors selling Bioventus stock.
Which institutional investors are buying Bioventus stock?
Within the previous quarter, BVS stock was bought by institutional investors including:
- Vanguard Group Inc.
- Driehaus Capital Management LLC
- American Century Companies Inc.
- BNP Paribas Financial Markets
- Dimensional Fund Advisors LP
- Sheets Smith Investment Management
- Nuveen Asset Management LLC
- Kennedy Capital Management LLC
During the last year, these company insiders have bought Bioventus stock:
- John A Bartholdson (Director)
- Juniper Investment Company, Ll (Major Shareholder)
- William A Hawkins (Director)
- Anthony P Bihl III (CEO)
Learn More investors buying Bioventus stock.